Thiamine deficiency

Thought Leadership & Innovation Foundation (TLI) Sponsors TACA Autism Conference, Showcases Autism Knowledge Gateway

Retrieved on: 
Mercoledì, Novembre 1, 2023
Education, Other Health, Health, Philanthropy, Training, Research, Family, Foundation, Consumer, Science, Parenting, Knowledge, Developmental disability, Spectrum, Seizure, The Autism Community in Action, Chronic pain, Autism spectrum, MD, Face, Conference, Mentorship, FAAFP, Thiamine deficiency, TACA, Information Technology and Innovation Foundation, Ferroptosis, Gateway, Public, Puberty, ASD, TLI, GABA, Parent, Dietary supplement

“This remarkable event served as a lifeline for families touched by autism, providing them with direct access to renowned experts, The Autism Community in Action (TACA) mentors, sponsors, vendors and like-minded families from across the nation,” says Shawn Murphy, vice president, TLI.

Key Points: 
  • “This remarkable event served as a lifeline for families touched by autism, providing them with direct access to renowned experts, The Autism Community in Action (TACA) mentors, sponsors, vendors and like-minded families from across the nation,” says Shawn Murphy, vice president, TLI.
  • Additionally, TLI sponsored a think tank session which served as a hub of innovation where emerging research on seizures, intracellular ferroptosis, GABA and purine signaling networks, thiamine deficiency, chronic pain relief and the groundbreaking Autism Knowledge Gateway were showcased.
  • The Autism Knowledge Gateway is a dynamic resource in development.
  • A collaborative chat room within the Gateway facilitates in-depth discussions of case studies and current research among clinicians.

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis

Retrieved on: 
Venerdì, Agosto 16, 2019
FDA, Clinical trials, Biotechnology, Pharmaceutical, Health, General Health, Oncology, Chemical compounds, Nutrition, Thiamine, Organic compounds, RTT, Vitamin deficiencies, Pyrazoles, Thiamine deficiency, Ruxolitinib, Myelofibrosis, Myelofibrosis, JAKARTA, INREBIC®, Celgene

We are excited to provide INREBIC as a new treatment option that may be used in patients with myelofibrosis, including patients previously treated with ruxolitinib.

Key Points: 
  • We are excited to provide INREBIC as a new treatment option that may be used in patients with myelofibrosis, including patients previously treated with ruxolitinib.
  • Thiamine levels should be assessed in all patients prior to starting INREBIC, periodically during treatment, and as clinically indicated.1 Do not start INREBIC in patients with thiamine deficiency; replete thiamine prior to treatment initiation.
  • Dosage reductions due to an adverse reaction during the randomized treatment period occurred in 19% of patients who received INREBIC.
  • INREBIC is a much-welcomed new treatment for the myelofibrosis community, said Ann Brazeau, Chief Executive Officer and Founder, MPN Advocacy and Education International.

The J.M. Smucker Company Issues Voluntary Recall of Specific Lots of 9Lives® Protein Plus® Wet, Canned Cat Food Due to Low Levels of Thiamine (Vitamin B1)

Retrieved on: 
Venerdì, Dicembre 7, 2018
Nutrition, Thiamine, RTT, Vitamin deficiencies, Thiamine deficiency, SJM

Cats fed diets low in thiamine for several weeks may be at risk for developing a thiamine deficiency.

Key Points: 
  • Cats fed diets low in thiamine for several weeks may be at risk for developing a thiamine deficiency.
  • Symptoms of deficiency displayed by an affected cat can be gastrointestinal or neurological in nature.
  • In advanced cases, neurological signs can develop, which include ventroflexion (bending towards the floor) of the neck, wobbly walking, circling, falling, and seizures.
  • For more than 120 years, The J. M. Smucker Company (NYSE: SJM) has brought families together to share memorable meals and moments.